Interview with Bart DeCorte: Outsourcing – how to choose the right CRO?

Drug-discovery outsourcing in the pharmaceutical industry has changed dramatically in the past 20 years. While the last century was mostly dominated by large pharmaceutical companies that executed all science within the walls of their organization, drug-discovery outsourcing has now become an integral part of the execution of research and early development (R&D) in biotech companies and large pharmaceutical organizations alike.

Earlier this year, Bart DeCorte, VP of Business development at MercachemSyncom, captured that remarkable transformation in a perspective article in the Journal of Medicinal Chemistry. In this interview he elaborates.

Drug-discovery and development organizations will most likely continue to rely on CRO partners to execute their drug-discovery programs. Before signing, clients should do their homework and reflect on the attributes they are looking for in a CRO. The success of any drug-discovery undertaking will depend greatly on the people who execute the science. The right partner can mean the difference between success and failure.

Related article from J. Med. Chem.:
https://doi.org/10.1021/acs.jmedchem.0c00176

 
 

Development Centres of Excellence Network Lead Optimization Hit Generation Lead Optimization
 
 
 
 
 

Development Centres of Excellence Network Lead Optimization Hit Generation Lead Optimization
 
 
 
Scroll to top